Trial Profile
An Open-Label, Phase 3 Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics; Registrational
- Sponsors Takeda
- 11 Apr 2024 Planned initiation date changed from 29 Jul 2024 to 30 Sep 2024.
- 17 Oct 2023 Status changed to not yet recruiting.
- 01 Mar 2016 Location and trial focus is assumed.